# A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT04434196** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 16 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** CC-99282
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04434196
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-21
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04434196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04434196, "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04434196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*